Apixaban or Enoxaparin After Head and Neck Cancer Surgery

This study is looking at whether apixaban (a pill) is a safe and easier way to prevent blood clots after head and neck cancer surgery compared to enoxaparin (a daily shot). Both medicines aim to prevent venous thromboembolism (blood clots in veins). Researchers want to see if apixaban can be used safely, if patients prefer it, and how well they follow the treatment plan. You could be eligible if you are between 18 and 89 years old and are having head and neck cancer surgery. The study plans to enroll 76 participants and is currently unclear on its status.

Study design: This study will compare two groups of participants, with one group taking apixaban and the other taking enoxaparin. It aims to enroll 76 participants.
What's involved: Participants will take either apixaban (twice daily pill) or enoxaparin (daily shot) for 10 days after surgery. You will need to provide informed consent and comply with study procedures.
Compensation: Not stated in the trial record.
Follow-up: Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

Recruiting

PHASE4Ages 18–89InterventionalPrevention

Kiranya Arnold

~76 participants

Updated 2025-10-08 on ClinicalTrials.gov

What's tested:EnoxaparinApixaban

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Study enrollment rate.

Measured over From study start until target enrollment is reached (up to 24 months).

Conditions

Venous Thromboembolism

Head and Neck Cancer

Where it's being run

1 sites across 1 states

New York1

Who to contact

Laine Abernathy, MS

[email protected]

315-464-5980

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Provide signed and dated informed consent.

Be willing and able to comply with study procedures and follow-up.

Be 18-89 years old (male or female).

Have a negative pregnancy test within 24 hours before surgery (if woman of childbearing potential).

Have biopsy-proven head and neck cancer, or a suspected cancer awaiting tissue diagnosis (can be confirmed by frozen section at surgery).

Be scheduled for major inpatient or outpatient oncologic head and neck surgery (defined as \>45 minutes operative time).

Be an appropriate surgical candidate (adequate performance status).

Squamous cell carcinoma of oral cavity, hypopharynx, larynx, nasal cavity

Malignancies from major salivary glands

Non-melanoma skin cancers (squamous cell, basal cell, Merkel cell carcinoma)

Unknown primary tumors of head and neck

Exclusion

Lack a tissue diagnosis of head and neck cancer during the study period.

Have one of these conditions instead of eligible cancer: Benign disease; Primary thyroid cancer (lower VTE risk); Lymphoma (not primarily surgical); or Melanoma

Fail to undergo definitive head and neck oncologic surgery (e.g., only diagnostic biopsy).

Have surgery limited to tissue diagnosis only (e.g., direct laryngoscopy, excisional lymph node biopsy).

Be unable (patient or caregiver) to administer the study drug.

Have a positive pregnancy test on the day of surgery.

Have a known history of prior DVT or PE (since extended anticoagulation would be indicated).

Have hereditary or acquired bleeding/clotting disorders.

Have severe renal impairment (CrCl \<30 mL/min).

Have conditions that, in the investigator's judgment, make study participation unsafe or confound results.

What this trial measures

Study enrollment rate.From study start until target enrollment is reached (up to 24 months).
Enrollment rate will be calculated as the number of participants enrolled, divided by the number of eligible participants, multiplied by 100%.

Trialytics